| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
70,000,000 |
| Market
Cap: |
148.40(M) |
| Last
Volume: |
140,704 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.841 - $2.03 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 7.8 |
| Insider 6 Months : 7.8 |
| Insider 3/6 Months : 15.6 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile SELLAS Life Sciences Group is a late-stage clinical biopharmaceutical company focused on developing cancer immunotherapeutics for a range of cancer indications. Co.'s product candidates include galinpepimut-S (GPS) and nelipepimut-S (NPS). Co.'s primary product candidate, GPS, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center that targets the Wilms tumor 1 protein, which is present in 20 or more cancer types. NPS is a cancer immunotherapy targeting the human epidermal growth factor receptor 2 expressing cancers.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
50,000 |
50,000 |
50,000 |
50,000 |
| Total Buy Value |
$84,600 |
$84,600 |
$84,600 |
$84,600 |
| Total People Bought |
3 |
3 |
3 |
3 |
| Total Buy Transactions |
3 |
3 |
3 |
3 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2025-04-03 |
2024-12-31 |
2024-07-02 |
2023-07-03 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Van Nostrand Robert L |
Director |
– • – |
2025-06-12 |
4 |
B |
$1.48 |
$14,800 |
D/D |
10,000 |
20,400 |
2.39 |
26% |
|
| Wasman Jane |
Director |
– • – |
2025-05-30 |
4 |
B |
$1.69 |
$33,800 |
D/D |
20,000 |
30,400 |
2.39 |
22% |
|
| Kalin Katherine Bach |
Director |
– • – |
2025-05-22 |
4 |
B |
$1.80 |
$36,000 |
D/D |
20,000 |
41,000 |
2.39 |
18% |
|
| Wasman Jane |
Director |
– • – |
2025-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
22,900 |
|
- |
|
| Van Nostrand Robert L |
Director |
– • – |
2025-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
22,900 |
|
- |
|
| Varian John |
Director |
– • – |
2025-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
22,900 |
|
- |
|
| Kalin Katherine Bach |
Director |
– • – |
2025-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
21,000 |
|
- |
|
| Cicic Dragan |
SVP, Chief Development Officer |
• – – |
2025-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
194,300 |
309,628 |
|
- |
|
| Stergiou Andelos M. |
President and CEO |
• • – |
2025-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
500,900 |
859,032 |
|
- |
|
| Scheinberg David A |
Director |
– • – |
2025-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
23,082 |
|
- |
|
| Burns John Thomas |
CFO |
• – – |
2025-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
194,300 |
299,062 |
|
- |
|
| Cicic Dragan |
SVP, Chief Development Officer |
• – – |
2024-12-04 |
4 |
D |
$1.13 |
$9,329 |
D/D |
(8,256) |
115,328 |
|
- |
|
| Stergiou Andelos M. |
President and CEO |
• • – |
2024-12-04 |
4 |
D |
$1.13 |
$31,967 |
D/D |
(28,289) |
358,132 |
|
- |
|
| Burns John Thomas |
CFO |
• – – |
2024-12-04 |
4 |
D |
$1.13 |
$8,096 |
D/D |
(7,165) |
104,762 |
|
- |
|
| Cicic Dragan |
SVP, Chief Development Officer |
• – – |
2024-06-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
118,584 |
|
6% |
|
| Scheinberg David A |
Director |
– • – |
2024-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
10,582 |
|
- |
|
| Wood Barbara A |
EVP, Gen. Counsel, Corp. Sec. |
• – – |
2024-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
117,225 |
|
- |
|
| Francomano Robert |
Chief Commercial Officer |
• – – |
2024-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
40,918 |
|
- |
|
| Van Nostrand Robert L |
Director |
– • – |
2024-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
10,400 |
|
- |
|
| Burns John Thomas |
CFO |
• – – |
2024-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
47,000 |
101,927 |
|
- |
|
| Varian John |
Director |
– • – |
2024-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
10,400 |
|
- |
|
| Kalin Katherine Bach |
Director |
– • – |
2024-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
8,500 |
|
- |
|
| Stergiou Andelos M. |
President and CEO |
• • – |
2024-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
159,000 |
376,421 |
|
- |
|
| Wasman Jane |
Director |
– • – |
2024-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
10,400 |
|
- |
|
| Wood Barbara A |
EVP, Gen. Counsel, Corp. Sec. |
• – – |
2023-12-06 |
4 |
D |
$1.08 |
$4,449 |
D/D |
(4,119) |
82,225 |
|
- |
|
99 Records found
|
|
Page 1 of 4 |
|
|
0.04 (1.92%) 
